AbbVie and FutureGen Biopharmaceutical have announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development, whilst utilising FutureGen’s Structure-based Targeted Evolution Platform (STEP) technology platform.
FG-M701 is a fully human monoclonal antibody targeting TL1A, a clinically validated target in IBD. FG-M701 is uniquely engineered with potential best-in-class functional characteristics compared to first-generation TL1A antibodies with the goal to drive greater efficacy and less frequent dosing as a therapy for IBD.
“The prevalence of IBD continues to increase, and many people living with ulcerative colitis and Crohn’s disease do not respond to current therapies,” said Jonathon Sedgwick, PhD, Senior Vice President and Global Head Of Discovery Research, AbbVie. “AbbVie’s mission to raise the standard of care includes the pursuit of transformative therapies that help more patients living with autoimmune diseases achieve remission. We look forward to our collaboration with FutureGen in advancing development of FG-M701 for the treatment of IBD.”
“We are very pleased to partner with AbbVie, a world-leader in the development and commercialisation of innovative inflammation and autoimmune therapies,” said Zhaoyu Jin, PhD Founder and Chief Executive Officer, FutureGen Biopharmaceutical. “We believe that AbbVie is a great partner, with the ability to apply their expertise and global scale to realizing FG-M701’s therapeutic potential and rapidly advancing this therapy for patients suffering from IBD. The collaboration with AbbVie also highlights FutureGen’s ability to generate potential best-in-class product candidates with our proprietary STEP technology platform.”